Analystreport

Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Barclays PLC from $90.00 to $95.00. They now have an "equal weight" rating on the

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com